Pulmonary arterial hypertension treatment drugs——WINREVAIR
10.13699/j.cnki.1001-6821.2025.01.020
- VernacularTitle:治疗肺动脉高压新药——WINREVAIR
- Author:
Yu-shan NING
1
;
Tao-hua SUN
;
An-jin CHEN
;
Rong WEI
Author Information
1. 青岛市市立医院,医学杂志编辑部,山东青岛 266011
- Publication Type:Journal Article
- Keywords:
WINREVAIR;
sotatercept-csrk;
recombinant activin receptor;
fusion protein;
pulmonary arterial hypertension
- From:
The Chinese Journal of Clinical Pharmacology
2025;41(1):96-99
- CountryChina
- Language:Chinese
-
Abstract:
The active ingredient of WINREVAIR,sotatercept-csrk,is a recombinant activin receptor ⅡA-Fc(ActRⅡA-Fc)fusion protein that improves pro-proliferation(ActRⅡA/Smad2/3-mediated)and anti-proliferation(BMPRⅡ/Smad 1/5/8-mediated)signals,thereby regulating vascular proliferation.In March 2024,WINREVAIR was approved by the U.S.Food and Drug Administration for the treatment of pulmonary arterial hypertension(PAH)in adults.Clinical studies have shown that WINREVAIR can improve exercise capacity and reduce the incidence of all-cause death or clinical worsening of PAH by 84％.Common adverse drugreactions include headache,epistaxis,rash,etc.
